NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis $0.72 -0.01 (-1.60%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.75 +0.02 (+3.44%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Assertio Stock (NASDAQ:ASRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Assertio alerts:Sign Up Key Stats Today's Range$0.72▼$0.7550-Day Range$0.62▼$0.7752-Week Range$0.51▼$1.38Volume163,251 shsAverage Volume220,546 shsMarket Capitalization$69.35 millionP/E RatioN/ADividend YieldN/APrice Target$2.63Consensus RatingBuy Company Overview Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois. Read More Assertio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreASRT MarketRank™: Assertio scored higher than 37% of companies evaluated by MarketBeat, and ranked 715th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAssertio has only been the subject of 2 research reports in the past 90 days.Read more about Assertio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Assertio are expected to grow in the coming year, from ($0.15) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssertio has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Assertio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.87% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 21.7, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently decreased by 4.10%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.87% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 21.7, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently decreased by 4.10%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Assertio this week, compared to 1 article on an average week.Search Interest7 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows4 people have added Assertio to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Assertio's insider trading history. Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address ASRT Stock News HeadlinesATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action LawsuitAugust 7 at 11:46 AM | globenewswire.comBerger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) InvestorsAugust 6 at 3:41 PM | prnewswire.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025August 5 at 8:30 AM | globenewswire.comInvestors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 81% over the last five yearsJuly 12, 2025 | finance.yahoo.comAssertio Holdings, Inc. (ASRT) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comAssertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025May 19, 2025 | globenewswire.comAssertio outlines 2025 transformation phase with $108M-$123M revenue guidance while advancing Rolvedon and Sympazan growthMay 13, 2025 | seekingalpha.comSee More Headlines ASRT Stock Analysis - Frequently Asked Questions How have ASRT shares performed this year? Assertio's stock was trading at $0.8711 at the start of the year. Since then, ASRT stock has decreased by 16.9% and is now trading at $0.7241. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) released its earnings results on Monday, May, 12th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.08. The company earned $26.49 million during the quarter, compared to analyst estimates of $27.52 million. Assertio had a negative trailing twelve-month return on equity of 24.87% and a negative net margin of 25.72%. Read the conference call transcript. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID). Company Calendar Last Earnings5/12/2025Today8/07/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASRT CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees20Year FoundedN/APrice Target and Rating Average Price Target for Assertio$2.63 High Price Target$3.50 Low Price Target$1.75 Potential Upside/Downside+262.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.58 million Net Margins-25.72% Pretax Margin-25.59% Return on Equity-24.87% Return on Assets-10.87% Debt Debt-to-Equity Ratio0.36 Current Ratio1.66 Quick Ratio1.35 Sales & Book Value Annual Sales$124.96 million Price / Sales0.56 Cash Flow$0.05 per share Price / Cash Flow14.99 Book Value$1.27 per share Price / Book0.57Miscellaneous Outstanding Shares95,780,000Free Float91,950,000Market Cap$69.35 million OptionableOptionable Beta0.28 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ASRT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.